{"id":"f-8b070c46fc-dc9d23e9-2768-5b33-8591-a95001e92f25","title":"Dr Reddy’s launches generic OTC ophthalmic solution in US market","description":"New Delhi, Jan 14 (PTI) Dr Reddy’s Laboratories on Wednesday said it has launched a generic over-the-counter ophthalmic solution for the treatment of itchy eyes in the US after getting approval from the US Food and Drug Administration","timestamp":1768395679,"category":"business","headline":"Dr Reddy’s launches generic OTC ophthalmic solution in US market","modifiedHeadline":"Dr. Reddy's Releases Generic Eye Drop in US","subCategories":["scid_4d81caea"],"region":"IN","bundleMetaData":{"bundleId":"7b48871c-c993-4956-b43d-6f46f8e1b036","bundleTitle":"Today In India","cardData":null},"iabCategoryId":"320","fcSummary":"Dr. Reddy's Laboratories has launched a generic over-the-counter ophthalmic solution for itchy eyes in the US, after FDA approval. Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% provides temporary relief from allergens. This addition expands Dr. Reddy's OTC eye-care offerings.","summary":"Dr. Reddy's offers relief to US itchy-eye sufferers! Launched generic OTC ophthalmic solution post FDA approval, a welcome remedy.","ctaUrl":"https://trends.glance.com/newz/India_News/IN/en/pti/f-8b070c46fc-dc9d23e9-2768-5b33-8591-a95001e92f25","sourceUrl":"http://www.ptinews.com","bannerImage":"https://g-mob.glance-cdn.com/public/dynamic/720x1280/4afe5ff6c9b433042e7fbe7d6a7177f9e9c4d4bc.webp","content":"

New Delhi, Jan 14 (PTI) Dr Reddy’s Laboratories on Wednesday said it has launched a generic over-the-counter ophthalmic solution for the treatment of itchy eyes in the US after getting approval from the US Food

\n\n

and Drug Administration.

Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7 per cent is an antihistamine eye drop, indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander.

\n\n

\"This launch adds to our current portfolio in the OTC eye-care space, which includes Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2 per cent and 0.1 per cent strengths,\" Dr Reddy’s Laboratories CEO North America Generics Milan Kalawadia said in a statement.

The first-to-market launch is a testament to the company’s deep capabilities in bringing store-brand equivalents of OTC brands in the US market, he added.

\n\n

The Pataday brand recorded sales of around USD 69.9 million in the US for the latest 52-week period ending December 27, 2025, according to NIQ data.

Dr Reddy’s shares on Wednesday ended 0.33 per cent down at Rs 1,186.45 apiece on BSE. PTI MSS

MSS BAL

BAL

","readDurationInMinutes":"2","author":{"name":"PTI","logo":"https://glance-mob.glance-cdn.com/public/bubble/jpeg/b4428283-3bff-45db-a5fa-15dccca89081.jpeg"},"ism":false,"analyticsResponses":[],"pointerSummary":["Dr. Reddy's launches generic OTC eye drop (Olopatadine 0.7%) in US after FDA approval.","Solution relieves itchy eyes from allergens like pollen, pet dander etc.","Pataday brand sales in US were $69.9M; Dr. Reddy's shares down 0.33%."],"tags":["DrReddys","OphthalmicSolution","OTC","USMarket","FDAApproval","ItchyEyes","OlopatadineHydrochloride","Antihistamine","EyeCare","MilanKalawadia","NorthAmericaGenerics","Pataday","NIQData","BSE"],"consent":true,"redirectionEnabled":false}

Dr Reddy’s launches generic OTC ophthalmic solution in US market

SUMMARY